Literature DB >> 35899067

Quantifying the immunological distinctiveness of emerging SARS-CoV-2 variants in the context of prior regional herd exposure.

Michiel J M Niesen1, Karthik Murugadoss1, Patrick J Lenehan1, Aron Marchler-Bauer2, Jiyao Wang2, Ryan Connor2, J Rodney Brister2, A J Venkatakrishnan1, Venky Soundararajan1.   

Abstract

The COVID-19 pandemic has seen the persistent emergence of immune-evasive SARS-CoV-2 variants under the selection pressure of natural and vaccination-acquired immunity. However, it is currently challenging to quantify how immunologically distinct a new variant is compared to all the prior variants to which a population has been exposed. Here, we define "Distinctiveness" of SARS-CoV-2 sequences based on a proteome-wide comparison with all prior sequences from the same geographical region. We observe a correlation between Distinctiveness relative to contemporary sequences and future change in prevalence of a newly circulating lineage (Pearson r = 0.75), suggesting that the Distinctiveness of emergent SARS-CoV-2 lineages is associated with their epidemiological fitness. We further show that the average Distinctiveness of sequences belonging to a lineage, relative to the Distinctiveness of other sequences that occur at the same place and time (n = 944 location/time data points), is predictive of future increases in prevalence (Area Under the Curve, AUC = 0.88 [95% confidence interval 0.86 to 0.90]). By assessing the Delta variant in India versus Brazil, we show that the same lineage can have different Distinctiveness-contributing positions in different geographical regions depending on the other variants that previously circulated in those regions. Finally, we find that positions that constitute epitopes contribute disproportionately (20-fold higher than the average position) to Distinctiveness. Overall, this study suggests that real-time assessment of new SARS-CoV-2 variants in the context of prior regional herd exposure via Distinctiveness can augment genomic surveillance efforts.
© The Author(s) 2022. Published by Oxford University Press on behalf of National Academy of Sciences.

Entities:  

Year:  2022        PMID: 35899067      PMCID: PMC9308564          DOI: 10.1093/pnasnexus/pgac105

Source DB:  PubMed          Journal:  PNAS Nexus        ISSN: 2752-6542


  41 in total

1.  Amino acid substitution matrices from protein blocks.

Authors:  S Henikoff; J G Henikoff
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

2.  Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.

Authors:  Galit Alter; Jingyou Yu; Jinyan Liu; Abishek Chandrashekar; Erica N Borducchi; Lisa H Tostanoski; Katherine McMahan; Catherine Jacob-Dolan; David R Martinez; Aiquan Chang; Tochi Anioke; Michelle Lifton; Joseph Nkolola; Kathryn E Stephenson; Caroline Atyeo; Sally Shin; Paul Fields; Ian Kaplan; Harlan Robins; Fatima Amanat; Florian Krammer; Ralph S Baric; Mathieu Le Gars; Jerald Sadoff; Anne Marit de Groot; Dirk Heerwegh; Frank Struyf; Macaya Douoguih; Johan van Hoof; Hanneke Schuitemaker; Dan H Barouch
Journal:  Nature       Date:  2021-06-09       Impact factor: 49.962

3.  BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.

Authors:  Noa Dagan; Noam Barda; Eldad Kepten; Oren Miron; Shay Perchik; Mark A Katz; Miguel A Hernán; Marc Lipsitch; Ben Reis; Ran D Balicer
Journal:  N Engl J Med       Date:  2021-02-24       Impact factor: 91.245

4.  Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.

Authors:  Ann R Falsey; Magdalena E Sobieszczyk; Ian Hirsch; Stephanie Sproule; Merlin L Robb; Lawrence Corey; Kathleen M Neuzil; William Hahn; Julie Hunt; Mark J Mulligan; Charlene McEvoy; Edwin DeJesus; Michael Hassman; Susan J Little; Barbara A Pahud; Anna Durbin; Paul Pickrell; Eric S Daar; Larry Bush; Joel Solis; Quito Osuna Carr; Temitope Oyedele; Susan Buchbinder; Jessica Cowden; Sergio L Vargas; Alfredo Guerreros Benavides; Robert Call; Michael C Keefer; Beth D Kirkpatrick; John Pullman; Tina Tong; Margaret Brewinski Isaacs; David Benkeser; Holly E Janes; Martha C Nason; Justin A Green; Elizabeth J Kelly; Jill Maaske; Nancy Mueller; Kathryn Shoemaker; Therese Takas; Richard P Marshall; Menelas N Pangalos; Tonya Villafana; Antonio Gonzalez-Lopez
Journal:  N Engl J Med       Date:  2021-09-29       Impact factor: 176.079

5.  Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.

Authors:  Yunlong Cao; Jing Wang; Fanchong Jian; Tianhe Xiao; Weiliang Song; Ayijiang Yisimayi; Weijin Huang; Qianqian Li; Peng Wang; Ran An; Jing Wang; Yao Wang; Xiao Niu; Sijie Yang; Hui Liang; Haiyan Sun; Tao Li; Yuanling Yu; Qianqian Cui; Shuo Liu; Xiaodong Yang; Shuo Du; Zhiying Zhang; Xiaohua Hao; Fei Shao; Ronghua Jin; Xiangxi Wang; Junyu Xiao; Youchun Wang; Xiaoliang Sunney Xie
Journal:  Nature       Date:  2021-12-23       Impact factor: 49.962

6.  Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition.

Authors:  Allison J Greaney; Tyler N Starr; Pavlo Gilchuk; Seth J Zost; Elad Binshtein; Andrea N Loes; Sarah K Hilton; John Huddleston; Rachel Eguia; Katharine H D Crawford; Adam S Dingens; Rachel S Nargi; Rachel E Sutton; Naveenchandra Suryadevara; Paul W Rothlauf; Zhuoming Liu; Sean P J Whelan; Robert H Carnahan; James E Crowe; Jesse D Bloom
Journal:  Cell Host Microbe       Date:  2020-11-19       Impact factor: 31.316

7.  Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.

Authors:  Bette Korber; Will M Fischer; Sandrasegaram Gnanakaran; Hyejin Yoon; James Theiler; Werner Abfalterer; Nick Hengartner; Elena E Giorgi; Tanmoy Bhattacharya; Brian Foley; Kathryn M Hastie; Matthew D Parker; David G Partridge; Cariad M Evans; Timothy M Freeman; Thushan I de Silva; Charlene McDanal; Lautaro G Perez; Haili Tang; Alex Moon-Walker; Sean P Whelan; Celia C LaBranche; Erica O Saphire; David C Montefiori
Journal:  Cell       Date:  2020-07-03       Impact factor: 66.850

8.  Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant.

Authors:  Leonid Yurkovetskiy; Xue Wang; Kristen E Pascal; Christopher Tomkins-Tinch; Thomas P Nyalile; Yetao Wang; Alina Baum; William E Diehl; Ann Dauphin; Claudia Carbone; Kristen Veinotte; Shawn B Egri; Stephen F Schaffner; Jacob E Lemieux; James B Munro; Ashique Rafique; Abhi Barve; Pardis C Sabeti; Christos A Kyratsous; Natalya V Dudkina; Kuang Shen; Jeremy Luban
Journal:  Cell       Date:  2020-09-15       Impact factor: 66.850

9.  SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting.

Authors:  Adeel A Butt; Saad B Omer; Peng Yan; Obaid S Shaikh; Florian B Mayr
Journal:  Ann Intern Med       Date:  2021-07-20       Impact factor: 25.391

10.  An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status.

Authors:  Sheila F Lumley; Gillian Rodger; Bede Constantinides; Nicholas Sanderson; Kevin K Chau; Teresa L Street; Denise O'Donnell; Alison Howarth; Stephanie B Hatch; Brian D Marsden; Stuart Cox; Tim James; Fiona Warren; Liam J Peck; Thomas G Ritter; Zoe de Toledo; Laura Warren; David Axten; Richard J Cornall; E Yvonne Jones; David I Stuart; Gavin Screaton; Daniel Ebner; Sarah Hoosdally; Meera Chand; Derrick W Crook; Anne-Marie O'Donnell; Christopher P Conlon; Koen B Pouwels; A Sarah Walker; Tim E A Peto; Susan Hopkins; Timothy M Walker; Nicole E Stoesser; Philippa C Matthews; Katie Jeffery; David W Eyre
Journal:  Clin Infect Dis       Date:  2022-04-09       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.